What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?

Every investor in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek is a smaller company with a market capitalization of zł544m, so it may still be flying under the radar of many institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutions own shares in the company. Let's delve deeper into each type of owner, to discover more about BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek.

Check out our latest analysis for BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek

What Does The Institutional Ownership Tell Us About BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

As you can see, institutional investors have a fair amount of stake in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's earnings history below. Of course, the future is what really matters.

Hedge funds don't have many shares in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek. OPDF S.A. is currently the largest shareholder, with 8.1% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 7.9% and 7.7%, of the shares outstanding, respectively. Waldemar Sierocki, who is the third-largest shareholder, also happens to hold the title of Member of Supervisory Board.

We also observed that the top 9 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. As far I can tell there isn't analyst coverage of the company, so it is probably flying under the radar.

Insider Ownership Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our information suggests that insiders maintain a significant holding in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.. It has a market capitalization of just zł544m, and insiders have zł152m worth of shares in their own names. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.

General Public Ownership

The general public holds a 49% stake in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Private Company Ownership

Our data indicates that Private Companies hold 17%, of the company's shares. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For instance, we've identified 1 warning sign for BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek that you should be aware of.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

If you’re looking to trade BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
^*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.